相关实验视频
Updated: Jun 13, 2025

09:36
Assessment of Child Anthropometry in a Large Epidemiologic Study
Published on: February 2, 2017
27.0K
用生长激素治疗的妊娠年龄小的儿童的肥胖反弹时间:来自LG生长研究数据的结果
Ji Hyun Kim1, Su Jin Kim2, In Hyuk Chung3
1Department of Pediatrics, Dongguk University Ilsan Hospital, Goyang, Korea.
Journal of Korean medical science
|February 4, 2025
概括
对于妊娠年龄 (SGA) 较小而没有追赶成长的儿童的肥胖反弹 (AR) 发生的时间比一般人群晚. 在这个队列中,AR时间没有显著影响青春期开始或成长结果.
科学领域:
- 儿科 儿科 儿科
- 内分泌学 在内分泌学.
- 增长和发展 增长和发展
背景情况:
- 肥胖反弹 (AR) 是与肥胖和青春期相关的关键生长阶段.
- 有限的研究存在于韩国儿童的AR时间出生小的妊娠年龄 (SGA).
研究的目的:
- 在没有追赶增长 (CUG) 的SGA儿童中确定AR时间,接受生长激素 (GH) 治疗.
- 确定影响AR时间的因素.
- 检查AR对青春期开始和GH治疗有效性的影响.
主要方法:
- 对LG生长研究数据的分析,这是一项多中心观察性临床试验.
- 包括151名出生于SGA但没有CUG的青春期前儿童.
- 评估AR时间,青春期开始和GH治疗结果.
主要成果:
- 15%的儿童在4-5岁时有RA,42%在5-6岁时有RA,27%在6-7岁时有RA,7岁后有16%有RA.
- 在初始高度SDS和AR定时之间发现了正相关性.
- 在AR时间和青春期发作或GH疗法的有效性之间没有显著的相关性.
结论:
- 没有CUG的SGA儿童的AR似乎比一般人群晚发生.
- 在这个队列中,AR的时间与青春期开始或成长结果没有显著的关系.
- 提供了关于特定SGA群体AR时间和增长的见解.
相关概念视频
Signs of Puberty
279
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
279
Insulin: Dosing Regimen and Adverse Effects
157
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
157
Nature and Nurture
20.4K
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
20.4K
Hypoglycemia and Glucagon
216
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
216
Obesity
411
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
411
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306

